You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Expression and association of HER2 with prognosis in early-stage (T1–T2N0M0) non-small cell lung cancer
|
|---|---|
| Published in |
Tumor Biology, June 2012
|
| DOI | 10.1007/s13277-012-0429-9 |
| Pubmed ID | |
| Authors |
Qing Xia, Zhihua Zhu, Jian Wang, Dongrong Situ, Ningning Zhou, Wenqi Jang |
| Abstract |
The expression of human epidermal growth factor receptor 2 (HER2) is related to tumor progression in many human malignancies. This study evaluated the significance of HER2 in early-stage non-small cell lung cancer (NSCLC). Specimens were obtained from 172 patients with early-stage (T1-T2N0M0) NSCLC, which included T1N0M0 (n = 52) and T2N0M0 (n = 120). The expression of HER2 was determined by immunohistochemistry (IHC). HER2 expression and its relationship with clinicopathological parameters and survival were analyzed. The expression of HER2 was significantly higher in the non-squamous cell carcinoma than in the squamous cell carcinoma (74.3 % vs. 53.7 %, p = 0.008). HER2 expression and tumor size were independent prognostic indicators in the multivariate analysis (p = 0.007 and p = 0.015, respectively). Expression of HER2 indicated a worse 5-year overall survival (65 % vs. 86 %, p = 0.014), especially for stages IB and IIA diseases (p = 0.035 and p = 0.043, respectively) and adenocarcinoma (p = 0.047). Therefore, HER2 may be related with the pathogenesis of NSCLC and act as an unfavorable prognostic factor in T1N0M0 and T2N0M0 NSCLC, especially in stages IB and IIA diseases. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 9% |
| Unknown | 10 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 36% |
| Student > Bachelor | 3 | 27% |
| Student > Ph. D. Student | 1 | 9% |
| Lecturer | 1 | 9% |
| Student > Master | 1 | 9% |
| Other | 1 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 55% |
| Agricultural and Biological Sciences | 3 | 27% |
| Biochemistry, Genetics and Molecular Biology | 1 | 9% |
| Nursing and Health Professions | 1 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 December 2012.
All research outputs
#18,325,190
of 22,691,736 outputs
Outputs from Tumor Biology
#1,369
of 2,621 outputs
Outputs of similar age
#126,427
of 164,444 outputs
Outputs of similar age from Tumor Biology
#14
of 18 outputs
Altmetric has tracked 22,691,736 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,621 research outputs from this source. They receive a mean Attention Score of 2.2. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,444 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.